AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - For most of the history of antibody discovery, the hard part was producing candidates. Generative models, high-throughput assays
Multi-year agreement covers a defined deployment of ReefIQ™ and specified LensAI™ capabilities
MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced a multi-year
AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
Commercial Priorities Unchanged; LensAI™ Remains in Contracted, Recurring Deployments with Life Sciences Customers
MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced
AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of
New white paper shows LensAI™ immunogenicity screening running at up to 43% lower cost per sequence on Amazon EC2 Hpc8a instances powered by AMD EPYC processors, making a critical drug-safety check practical at the
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
Senior appointments from Pfizer, Novartis, Arbor Biotechnologies, and Orum Therapeutics bring preclinical development, structural biology, and portfolio strategy depth as MindWalk prepares its programs for preclinical
AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The global market for artificial intelligence in drug discovery is projected to grow from $5.09 billion in 2026 to $17.56 billion by
As data platforms and industry analysts converge on the "ontology layer" as the missing piece of agentic AI, MindWalk outlines why life sciences needs a biological context layer of its own, and why ReefIQ™,
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /CNW/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound
Veteran Banker and Licensed Fiduciary to Serve on the Audit Committee and the Compensation, Nomination and Governance Committee
MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company,
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - For most of the last decade, predicting the three-dimensional shape of a protein complex was the kind of capability only a
Antibody-antigen inference ran approximately 5x faster than in MindWalk's prior environment. The deployment, run with engineering partners AMD and Vultr on AMD Instinct™ MI325X GPUs, demonstrates the model-agnostic
ReefIQ™ launched commercially, and a US$30 million unsecured credit facility commitment, drawn only as needed, adds balance-sheet flexibility with no dilution.
MindWalk Holdings Corp. ("MindWalk")
